Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.33 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
| ▸ | CCKBR | P32239 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 2/20 | 0.31 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.30 |
| ▸ | GRM5 | P41594 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30081471 | 0.74 | ALDH1A1 (0.45) | ALDH1A1HSD17B10OPRM1OPRL1 | |
| SCHEMBL928489 | 0.74 | ALDH1A1 (0.45) | ALDH1A1HSD17B10MAPK9PSMB8PRMT5 | |
| SCHEMBL115601 | 0.74 | ALDH1A1 (0.45) | ALDH1A1HSD17B10OPRM1OPRL1 | |
| SCHEMBL2093035 | 0.74 | ALDH1A1 (0.45) | ALDH1A1HSD17B10MAPK9EGFRPRMT5 | |
| SCHEMBL115602 | 0.74 | ALDH1A1 (0.45) | ALDH1A1HSD17B10PRMT5OPRM1OPRL1 | |
| SCHEMBL5562354 | 0.74 | ALDH1A1 (0.45) | ALDH1A1HSD17B10CCKBRPRMT5OPRM1 | |
| SCHEMBL6972765 | 0.74 | ALDH1A1 (0.45) | ALDH1A1HSD17B10PRMT5OPRM1OPRL1 | |
| SCHEMBL288616 | 0.74 | ALDH1A1 (0.45) | ALDH1A1HSD17B10PRMT5OPRM1OPRL1 | |
| SCHEMBL9853741 | 0.74 | ALDH1A1 (0.45) | ALDH1A1HSD17B10PRMT5OPRM1OPRL1 | |
| SCHEMBL29806829 | 0.74 | ALDH1A1 (0.45) | ALDH1A1HSD17B10MAPK9EGFRPRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 156 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110098292-A1 | New Compounds Useful for Treating CNS Disorders | ASTRAZENECA AB (SE) | 2011-04-28 | — | — | US | claimed |
| CN-1980922-A | New compounds useful for treating CNS disorders | ASTRAZENECA AB (SE) | 2007-06-13 | — | — | CN | claimed |
| EP-1765815-A2 | NEW COMPOUNDS USEFUL FOR TREATING CNS DISORDERS | AstraZeneca AB (SE) | 2007-03-28 | — | — | EP | claimed |
| WO-2006004507-A2 | NEW BENZOTHIAZOLE DERIVATIVES USEFUL FOR TREATING CNS DISORDERS | ASTRAZENECA AB (SE) | 2006-01-12 | — | — | WO | claimed |
| US-12637449-B2 | Organic compound and organic light emitting device including the same | LG DISPLAY CO., LTD. (KR) | 2026-05-26 | — | — | US | disclosed |
| US-20260103471-A1 | CYCLIC UREA THIAZOLYL COMPOUNDS FOR TREATMENT OF HSV | ASSEMBLY BIOSCIENCES INC (US) | 2026-04-16 | — | — | US | disclosed |
| US-20260014146-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-20250376478-A1 | CYCLIC UREA THIAZOLYL COMPOUNDS FOR TREATMENT OF HSV | ASSEMBLY BIOSCIENCES INC (US) | 2025-12-11 | — | — | US | disclosed |
| US-12478621-B2 | Substituted aminoquinolones as dgkalpha inhibitors for immune activation | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2025-11-25 | — | — | US | disclosed |
| US-20250270215-A1 | IMIDAZOLE DERIVATIVES AS ALK5 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2025-08-28 | — | — | US | disclosed |
| EP-4581029-A1 | CYCLIC UREA THIAZOLYL COMPOUNDS FOR TREATMENT OF HSV | Assembly Biosciences, Inc. (US) | 2025-07-09 | — | — | EP | disclosed |
| EP-4562014-A2 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | Cedilla Therapeutics, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| EP-2393806-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | Elan Pharmaceuticals Inc. (US) | 2011-12-14 | — | — | EP | disclosed |
| WO-2011100502-A1 | 7-AMINOFUROPYRIDINE DERIVATIVES | OSI Pharmaceuticals, LLC (US) | 2011-08-18 | — | — | WO | disclosed |
| US-20110098292-A1 | New Compounds Useful for Treating CNS Disorders | ASTRAZENECA AB (SE) | 2011-04-28 | — | — | US | disclosed |
| US-20100331335-A1 | Inhibitors of Jun N-Terminal Kinase | ELAN PHARMACETICALS, INC. | 2010-12-30 | — | — | US | disclosed |
| WO-2010091310-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | ELAN PHARMACEUTICALS, INC. (US) | 2010-08-12 | — | — | WO | disclosed |
| CN-1980922-A | New compounds useful for treating CNS disorders | ASTRAZENECA AB (SE) | 2007-06-13 | — | — | CN | disclosed |
| EP-1765815-A2 | NEW COMPOUNDS USEFUL FOR TREATING CNS DISORDERS | AstraZeneca AB (SE) | 2007-03-28 | — | — | EP | disclosed |
| WO-2006004507-A2 | NEW BENZOTHIAZOLE DERIVATIVES USEFUL FOR TREATING CNS DISORDERS | ASTRAZENECA AB (SE) | 2006-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260103471-A1 | CYCLIC UREA THIAZOLYL COMPOUNDS FOR TREATMENT OF HSV | TK1, UNG, SMCHD1 | ALDH1A1 3205/4885HSD17B10 2667/4885MAPK9 1204/4885 |
| US-12478621-B2 | Substituted aminoquinolones as dgkalpha inhibitors for immune activation | DGKK, DGKG, DGKA | ALDH1A1 3915/4885HSD17B10 3531/4885MAPK9 416/4885 |
| US-12637449-B2 | Organic compound and organic light emitting device including the same | CRY1, NR2E3, CRY2 | ALDH1A1 289/4885HSD17B10 875/4885MAPK9 4313/4885 |
| US-20110098292-A1 | New Compounds Useful for Treating CNS Disorders | SLC18A2, PMP22, GAP43 | ALDH1A1 1045/4885HSD17B10 1386/4885MAPK9 3486/4885 |
| US-20250376478-A1 | CYCLIC UREA THIAZOLYL COMPOUNDS FOR TREATMENT OF HSV | TYMP, TK1, TREH | ALDH1A1 3189/4885HSD17B10 3385/4885MAPK9 2410/4885 |
| US-20250270215-A1 | IMIDAZOLE DERIVATIVES AS ALK5 INHIBITORS | ALK, TGFBR1, TGFBR2 | ALDH1A1 828/4885HSD17B10 3765/4885MAPK9 410/4885 |
| US-20100331335-A1 | Inhibitors of Jun N-Terminal Kinase | CHUK, MAPK6, MAPK3 | ALDH1A1 4529/4885HSD17B10 3960/4885MAPK9 16/4885 |
| US-20260014146-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CDK2, CDK20, CDK1 | ALDH1A1 3585/4885HSD17B10 1442/4885MAPK9 718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.